

Global Gemcitabine HCL Market: Rising Prevalence of Cancer to Drive Market Growth says AMI

Global Gemcitabine HCL Market Accounted for US\$ 674.2 Million in 2022 and is Anticipated to Witness CAGR of 7.2% from 2023 to 2031

HOUSTON, TEXAS, UNITED STATES, August 8, 2023 /EINPresswire.com/ -- Global [Gemcitabine HCL Market](#)

Summary

Gemcitabine HCL is a chemotherapy drug that is used to treat a variety of cancers, including pancreatic cancer, ovarian cancer, and non-small cell lung cancer. It is a type of antimetabolite, which means that it works by interfering with the DNA and RNA of cancer cells, causing them to die.

Before the COVID-19 pandemic, the gemcitabine HCL market showed steady growth. However, the pandemic caused a significant decline in demand due to manufacturing shutdowns, transportation restrictions, and reduced cancer diagnoses and treatments. As the prevalence of cancer rises and awareness of gemcitabine HCL benefits increases, the market is expected to recover, but at a slower pace than without the pandemic. The long-term impact of COVID-19 on the market highlights the importance of adapting to changing healthcare dynamics and maintaining sustained growth in the coming years.

Get PDF sample report with related graphs & charts (Pre & post COVID-19 impact analysis):

https://www.absolutemarketsinsights.com/request_sample.php?id=1648

Global Gemcitabine HCL Market Growth Drivers:

- Increasing Cancer Incidence and Prevalence - One key driver of the gemcitabine HCL market is the rising incidence and prevalence of cancer globally. According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with approximately 10 million deaths in 2021. The growing burden of cancer cases fuels the demand for chemotherapy drugs like Gemcitabine HCL. Academic research indicates a continuous increase in cancer cases over



the years, necessitating effective and widely used chemotherapy treatments, contributing to the growth of the gemcitabine HCL market.

- Expanding Applications in Multiple Indications - Gemcitabine HCL's versatility and efficacy in treating various cancers have expanded its applications in multiple indications. Clinical trials and studies have demonstrated Gemcitabine HCL's efficacy in treating breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other malignancies. The drug's well-established clinical benefits and ongoing research on its potential in different cancer types have driven its adoption and usage in a broad spectrum of oncology treatments.

- Continuous Advancements in Cancer Research and Treatment - The evolving landscape of cancer research and treatment is a significant driver for the gemcitabine HCL market. Advancements in oncology research have led to the development of targeted therapies and combination treatments with Gemcitabine HCL. Research papers and clinical trials demonstrate the incorporation of Gemcitabine HCL into novel treatment regimens, including immunotherapy and precision medicine approaches, further driving its demand and contributing to the overall growth of the market.

Speak to our analyst in case of queries before buying this report:

https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1648

Global Gemcitabine HCL Market Recent Developments:

- Some recent developments in the gemcitabine HCL market include the approval of new gemcitabine HCL products with improved efficacy and safety profiles; the expansion of the oncology market, which is a major driver of the gemcitabine HCL market; and government support for the use of gemcitabine HCL in some countries.
- Among the regions, Asia Pacific is expected to witness highest growth rate in the gemcitabine HCL market. The region's large patient population, increasing cancer incidence, and improving healthcare access have driven the demand for oncology drugs, including Gemcitabine HCL. Research and academic publications from Asia Pacific have indicated a surge in studies focusing on gemcitabine HCL's efficacy and application, reflecting the region's rapid growth in this market.

Global Gemcitabine HCL Market: Key Competitors

- o Accord Healthcare Inc.
- o Apotex Inc.
- o Eli Lilly & Co.
- o F. Hoffmann La Roche
- o Fresenius Kabi USA
- o Gland Pharma Ltd.
- o Hebei Changsan Biochemical Pharmaceutical Co., Ltd
- o Jiangsu Hansoh Pharmaceutical Group Co Ltd
- o Mylan Pharmaceuticals Inc.
- o Pfizer Inc. (Hospira Inc.)
- o Sagent Pharmaceuticals Inc.

- o Teva Pharmaceuticals Ltd.
- o Other Industry Participants

Global Gemcitabine HCL Market:

By Product Type

- o Injection
- o Solution

By Indication

- o Breast Cancer
- o Non-small Cell Lung Cancer
- o Pancreatic Cancer
- o Ovarian Cancer
- o Biliary Tract cancer
- o Others

[Purchase the latest in-depth Global Gemcitabine HCL Market Report](#)

By Region

- o North America (U.S., Canada, Mexico, Rest of North America)
- o Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- o Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- o Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- o Latin America (Brazil, Argentina, Rest of Latin America)

Top Reports

Global Recombinant Factor C Assay Market

<https://www.absolutemarketsinsights.com/reports/Global-Recombinant-Factor-C-Assay-Market-2023-%E2%80%93-2031--1432>

Global Osteoporosis Treatment Market

<https://www.absolutemarketsinsights.com/reports/Global-Osteoporosis-Treatment-Market-2022-%E2%80%93-2030-1414>

About Us:

[Absolute Markets Insights](#) assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill

their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:

Contact Name: Shreyas Tanna

Company: Absolute Markets Insights

Email Id: sales@absolutemarketsinsights.com

Phone: +1-510-420-1213

Website: www.absolutemarketsinsights.com

Shreyas Tanna

Absolute Markets Insights

+1 510-420-1213

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/648803655>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.